The majority (73%) of samples were classified as “immune infiltrated.” While there was no significant association between the degree of tumor infiltration and clinical benefit, there was an association observed between the presence of PBRM1 mutations and lower T-cell infiltration (p = 0.013). This evidence concerns the gene PBRM1 and neoplasm.